ATE552272T1 - Myostatin-isoform - Google Patents

Myostatin-isoform

Info

Publication number
ATE552272T1
ATE552272T1 AT05790714T AT05790714T ATE552272T1 AT E552272 T1 ATE552272 T1 AT E552272T1 AT 05790714 T AT05790714 T AT 05790714T AT 05790714 T AT05790714 T AT 05790714T AT E552272 T1 ATE552272 T1 AT E552272T1
Authority
AT
Austria
Prior art keywords
present
sequences
myostatin
muscle
splice variants
Prior art date
Application number
AT05790714T
Other languages
English (en)
Inventor
Ferenc Jeanplong
Christopher David Mcmahon
Original Assignee
Orico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NZ53569604A external-priority patent/NZ535696A/en
Application filed by Orico Ltd filed Critical Orico Ltd
Application granted granted Critical
Publication of ATE552272T1 publication Critical patent/ATE552272T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05790714T 2004-09-30 2005-09-30 Myostatin-isoform ATE552272T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ53569604A NZ535696A (en) 2004-09-30 2004-09-30 Myostatin splice variants ( MSV )
NZ53839605 2005-02-22
PCT/NZ2005/000250 WO2006036074A1 (en) 2004-09-30 2005-09-30 Myostatin isoform

Publications (1)

Publication Number Publication Date
ATE552272T1 true ATE552272T1 (de) 2012-04-15

Family

ID=36119161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790714T ATE552272T1 (de) 2004-09-30 2005-09-30 Myostatin-isoform

Country Status (6)

Country Link
US (2) US20080118487A1 (de)
EP (1) EP1799709B1 (de)
JP (1) JP5335239B2 (de)
AT (1) ATE552272T1 (de)
CA (1) CA2582940A1 (de)
WO (1) WO2006036074A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100898149B1 (ko) 2007-04-05 2009-05-19 주식회사 에스엔피 제네틱스 소의 근내지방도와 연관되어 있는 티틴-캡 다형성
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
WO2019195679A1 (en) * 2018-04-06 2019-10-10 Intrexon Corporation Tilapia with enhanced growth characteristics
US12202869B2 (en) 2019-03-01 2025-01-21 Knc Laboratories Co., Ltd. Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof
CA3211057A1 (en) * 2021-02-26 2022-09-01 Knc Laboratories Co., Ltd. Nucleic acid medicine expressing splicing variant of myostatin
CN115201474A (zh) * 2022-08-12 2022-10-18 万华普曼生物工程有限公司 一种新型冠状病毒抗体的快速检测试剂盒及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4487325A (en) 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
US7368534B2 (en) * 2000-01-18 2008-05-06 Orico Limited Myostatin and mimetics thereof
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP1578928B1 (de) * 2002-09-16 2010-03-17 The Johns Hopkins University Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
NZ529860A (en) * 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
CN1902221A (zh) * 2003-12-31 2007-01-24 先灵-普劳有限公司 基于中和表位的生长增强疫苗
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
CA2693378C (en) * 2006-08-03 2020-04-14 Myostin Therapeutics Pty Ltd Myostatin antagonists

Also Published As

Publication number Publication date
JP5335239B2 (ja) 2013-11-06
CA2582940A1 (en) 2006-04-06
JP2008514227A (ja) 2008-05-08
EP1799709B1 (de) 2012-04-04
EP1799709A4 (de) 2008-11-12
US20110258712A1 (en) 2011-10-20
EP1799709A1 (de) 2007-06-27
US8455448B2 (en) 2013-06-04
WO2006036074A1 (en) 2006-04-06
US20080118487A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
CY1124332T1 (el) Πεγκυλιωμενες ενωσεις ανασυνδυασμενης ανθρωπινης αυξητικης ορμονης
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
NO20111324A1 (no) Rekombinant MVA-virus
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
EA200601107A1 (ru) Композиции, получаемые из морских растений, для обеспечения питания для старческой и поврежденной окружающей средой кожи
DK1715887T3 (da) N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
ATE499105T1 (de) Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen
LU93259I2 (fr) LETIFEND (Protein Q)
EP1018976A4 (de) Behandlungskammer zur aufnahme des kopfes von versuchstieren
DE59510466D1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
ATE225803T1 (de) Peptid zur verringerung des triglyzeridspiegels des blutes und inhibitor für den anstieg des triglyzeridspiegels des blutes, der das peptid als aktiven bestandteil enthält
EP1799709A4 (de) Myostatin-isoform
DK1599215T3 (da) Anvendelse af tryptophanrige peptider fra mælkeproteinhydrolysat til behandling af overvægt og fedme
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
DE60324784D1 (de) Behandlung zur reduzierung der zunahme des körpergewichts
NO20075272L (no) Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser
FR2947454B1 (fr) Innovation destinee a l'homme et l'animal a base d'inhibiteurs naturels des proteases humaines associes a des plantes medicinales, indiquees dans toutes les pathologies